Eledon Pharmaceuticals, Inc. Common Stock ELDN
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $9.67 (+180.2% upside)
Key Stats
- Today's Range
- $3.41 – $3.58
- 50-Day Range
- $3.25 – $4.49
- 52-Week Range
- $1.35 – $4.60
- Volume
- 744K shs
- Average Volume
- 932K shs
- Market Cap
- $286.04 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.11%
- Days to Cover
- 1.13
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Related Stocks
Compare head-to-head: ELDN vs LLY·ELDN vs JNJ·ELDN vs ABBV·ELDN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.